BlackRock Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

BlackRock Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$893K	Sell	37,526 -843	-2%	-$24.1K	﹤0.01%	1917
2016 Q3	$1.41M	Sell	38,369 -4,172	-10%	-$120K	﹤0.01%	1640
2016 Q2	$949K	Buy	42,541 +98	+0.2%	+$2.44K	﹤0.01%	1778
2016 Q1	$883K	Buy	42,443 +1,130	+3%	+$27.9K	﹤0.01%	1801
2015 Q4	$1.25M	Sell	41,313 -5,845	-12%	-$177K	﹤0.01%	1611
2015 Q3	$1.17M	Buy	47,158 +3,860	+9%	+$115K	﹤0.01%	1592
2015 Q2	$1.39M	Sell	43,298 -11,477	-21%	-$438K	﹤0.01%	1444
2015 Q1	$1.96M	Buy	54,775 +189	+0.3%	+$5.18K	﹤0.01%	1245
2014 Q4	$1.24M	Sell	54,586 -48,073	-47%	-$972K	﹤0.01%	1377
2014 Q3	$1.99M	Buy	102,659 +1,124	+1%	+$31.8K	﹤0.01%	1176
2014 Q2	$3.69M	Buy	101,535 +61,368	+153%	+$2.09M	﹤0.01%	1032
2014 Q1	$1.56M	Buy	40,167 +34,247	+578%	+$1.22M	﹤0.01%	1282
2013 Q4	$169K	Buy	5,920 +609	+11%	+$17.9K	﹤0.01%	2750
2013 Q3	$190K	Buy	5,311 +24	+0.5%	+$876	﹤0.01%	2587
2013 Q2	$177K	Buy	+5,287	New	+$240K	﹤0.01%	2545

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Advisors's RIGL Position: Q4 2016 in Review

BlackRock Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 2.2% in Q4 2016, selling an estimated $24.1K and leaving 37,526 shares worth $893K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

BlackRock Advisors first reported a position in RIGL in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.69M in Q2 2014. 107 funds tracked by Wall St. Rank hold RIGL as of Q4 2016.

BlackRock Advisors held 37,526 shares of Rigel Pharmaceuticals worth $893K as of Q4 2016.
BlackRock Advisors sold 843 Rigel Pharmaceuticals shares in Q4 2016, an estimated $24.1K.
Rigel Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1917 holding.
BlackRock Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Rigel Pharmaceuticals position peaked at $3.69M in Q2 2014.
107 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.